Jerome Boyd-Kirkup
Seminars
Tuesday 13th October 2026
Presentation Preview: Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs
- Designing multi-mechanism, complementary dual payload ADCs to drive deep and durable responses across a broad range of solid tumors
- Pioneering the next generation of dual payload ADCs featuring rationally selected payload combinations designed to overcome treatment resistance to single-payload ADCs
- Contextualizing lead dual payload ADC, CLIO-8221, currently in clinical trials, with a second program expected to enter the clinic in late 2026
